首页> 美国卫生研究院文献>BMC Neuroscience >In vitro characterization of odorranalectin for peptide-based drug delivery across the blood–brain barrier
【2h】

In vitro characterization of odorranalectin for peptide-based drug delivery across the blood–brain barrier

机译:奥兰拉菌素的体外表征用于跨血脑屏障的基于肽的药物输送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe use of siRNA-based gene silencing has been recently underscored as a potential therapeutic strategy for the treatment of neurological disorders. However, the stability of siRNA and other small molecule therapeutics is challenged by their intrinsic instability and limited passage across the blood–brain barrier (BBB). Based on these premises, our objective was to characterize/optimize odorranalectin (OL), a small non-immunogenic lectin-like peptide, as a carrier for targeted delivery across the BBB. For this purpose, 5(6)-carboxyfluorescein-conjugated OL and scramble peptide were synthesized, and then their BBB cellular internalization/trafficking and stability were characterized versus temperature, pH and serum content in the media in hCMEC/D3 cells as a model of BBB endothelium. Specifically, integrity of the internalized peptide in cell lysates was analyzed by LC/MS while cellular distribution and intracellular trafficking of OL was examined by fluorescence microscopy with early-late endosome (pHRodo Red®) and lysosome (Lysotracker®) markers.
机译:背景技术最近强调了使用基于siRNA的基因沉默作为治疗神经系统疾病的潜在治疗策略。但是,siRNA和其他小分子疗法的稳定性受到其固有的不稳定性和穿过血脑屏障(BBB)的通道有限的挑战。基于这些前提,我们的目标是表征/优化作为非免疫原性凝集素样小肽的阿诺拉菌素(OL),作为跨BBB靶向递送的载体。为此目的,合成了5(6)-羧基荧光素偶联的OL和加扰肽,然后表征它们的BBB细胞内在化/运输和稳定性与hCMEC / D3细胞培养基中温度,pH和血清含量的关系,作为模型。 BBB内皮。具体而言,通过LC / MS分析细胞裂解物中内在化肽的完整性,同时使用早期晚期内体(pHRodo Red ®)和溶酶体(Lysotracker)通过荧光显微镜检查OL的细胞分布和细胞内运输®)标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号